

TABLE 1. Synthesis of Oxazolidin-2-ones **2 by PdI₂/KI-Catalyzed Oxidative Carbonylation of β -Amino Alcohols **1**^a**

entry	1	R ¹	R ²	1/PdI ₂	time (h)	yield of 2 (%) ^b
1 ^c	1a	H	H	2000	15	96 (90)
2	1b ^d	Me	H	2000	15	96 (91)
3	1c ^d	Ph	H	2000	8	93 (88) ^e
4	1d ^d	H	Me	2000	15	100 (96)
5	1e ^f	H	Ph	2000	3	97 (88)
6	1f ^d	H	Me ₂ CH	2000	15	88 ^g
7	1f ^d	H	Me ₂ CH	1000	15	94 (87) ^h
8	1g ⁱ	H	PhCH ₂	2000	15	83 ^j
9	1g ⁱ	H	PhCH ₂	1000	15	90 (81)


^a Unless otherwise noted, all reactions were carried out in DME (0.5 mmol/mL DME, 5–10 mmol scale based on **1**) at 100 °C under 20 atm of a 4/1 mixture of CO/air in the presence of PdI₂ in conjunction with 10 equiv of KI. ^b GLC yield (isolated yield) based on **1**. Substrate conversion was practically quantitative in all cases. ^c Substrate concentration was 0.25 mmol/mL DME. The reaction carried out with 0.5 mmol/mL DME led to a lower yield of **2a** (78%, by GLC). ^d Racemic. ^e *N,N*-Bis(2-hydroxy-2-phenylethyl)oxalamide **3c** (4%) was also formed. ^f *R* enantiomer. ^g *N,N*-Bis(1-hydroxymethyl-2-methylpropyl)oxalamide **3f** was also formed (10%). ^h Oxalamide **3f** was also formed (5%). ⁱ *S* enantiomer. ^j (*S,S*)-*N,N*-Bis(1-benzyl-2-hydroxyethyl)oxalamide **3g** (6%) was also formed

TABLE 2. Oxidative Carbonylation of 2-Aminophenol **4 to Benzoxazolidin-2-one **5**^a**

entry	sol-vent	P(CO) (atm)	P(air) (atm)	P(O ₂) (atm)	mmol 4 /mL solvent	1/KI/PdI ₂	yield of 5 (%) ^b	yield of 6 (%) ^b
10	MeOH	5	25	30	2000/200/1	0.5	traces	(62)
11	DME	16	4	-	2000/10/1	0.5	96	traces
12	DME	16	4	-	5000/10/1	0.5	65	traces
13	DME	16	4	-	5000/10/1	1	95 (89)	traces

^a All reactions were carried out at 100 °C for 15 h, 10–15 mmol scale based on **4**. ^b GLC yield (isolated yield) based on **4**. Substrate conversion was practically quantitative in all cases.

azolin-2-one **5** were obtained from the reaction of 2-aminophenol **4** under the original reaction conditions, while the main reaction product (62% isolated yield, entry 10, Table 2) corresponded to 2-aminophenoxazin-3-one **6** (questionmycin A, an antibiotic)⁵ deriving from an oxidative dimerization process without CO incorporation (eq 3).⁶ However, under the improved conditions reported in this work, the cyclocarbonylation product **5** was formed with a yield as high as 96%, **6** being present in the reaction mixture just in traces (entry 11). In this latter reaction, catalytic efficiencies up to 4750 mol of **5** per mol of PdI₂ were obtained by using a substrate concentration of 1 rather than 0.5 mmol/mL of DME starting with a 4/PdI₂ molar ratio of 5000 (entry 13).



In conclusion, we have found that the PdI₂/KI-catalyzed oxidative cyclocarbonylation of β -amino alcohols and

(5) For some recent data on pharmacological activity of **5**, see: Kim, D. S.; Jeong, H. J.; Bhat, K. P. L.; Park, S. Y.; Kang, S. H.; Yoo, E. H.; Lee, M.; Lee, H. W.; Krueger, R. J.; Kim, D. S. H. L. *Planta Med.* **2000**, *66*, 78–79. Igarashi, Y.; Keiichi, K.; Furumai, T. *J. Antibiot.* **1998**, *51*, 915–920.

2-aminophenol leading to the corresponding oxazolidin-2-ones can be carried out in high yields and excellent catalytic efficiencies by using a very simple catalytic system (PdI₂ + 10 mol of KI) in DME as the solvent under mildly oxidizing conditions.⁷ This atom-economical methodology⁸ represents a valuable alternative to the use of diethyl carbonate as an indirect carbonylation agent^{9,10} for the synthesis of this very important class of heterocyclic compounds.^{11–13}

Experimental Section

General Methods. Melting points are uncorrected. ¹H NMR and ¹³C NMR spectra were recorded at 300 and 75 MHz, respectively, with Me₄Si as internal standard. Chemical shifts and coupling constants (*J*) are given in ppm (δ) and in Hz,

(6) Formation of **5** from **3** and oxygen has been reported. For recent references, see: (a) Simandi, L. I.; Barna, T.; Nemeth, S. *J. Chem. Soc., Dalton Trans.* **1996**, 473–478. (b) Maruyama, K.; Moriguchi, T.; Mashino, T.; Nishinaga, A. *Chem. Lett.* **1996**, 819–820.

(7) Recently, the Pd(II)-catalyzed oxidative carbonylation of **1** to **2** carried out at room temperature and atmospheric pressure of CO with electrochemical reoxidation of Pd(0) has been reported: Chiarotto, I.; Feroci, M. *Tetrahedron Lett.* **2001**, *42*, 3451–3453. However, very low catalytic efficiencies were obtained (not higher than 9.6 mol of product per mol of Pd used) and the method required the use of an excess of a base such as NaOAc (4 equiv with respect to **1**) in addition to a supporting electrolyte (Bu₄NBF₄).

(8) For a recent review on the importance of the development of new atom-economical processes, see: Trost, B. M. *Acc. Chem. Res.* **2002**, *35*, 695–705.

(9) Gage, J. R.; Evans, D. A. *Org. Synth.* **1990**, *68*, 77–82. For a review on synthesis of **2**, see Ager, D. J.; Prakash, I.; Schaad, D. R. *Chem. Rev.* **1996**, *96*, 835–875. For some recent developments in oxazolidin-2-one synthesis, see: Feroci, M.; Gennaro, A.; Inesi, A.; Orsini, M.; Palombi, L. *Tetrahedron Lett.* **2002**, *43*, 5863–5865. Righi, G.; Potini, C.; Bovicelli, P. *Tetrahedron Lett.* **2002**, *43*, 5867–5869. Casado-Bellver, F. J.; Gonzalez-Rosende, M. E.; Asensio, A.; Jordà-Gregori, J. M.; Alvarez-Sorolla, A.; Sepulveda-Arques, J.; Orena, M.; Galeazzi, R. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1650–1654. Kawami, H.; Ikushima, Y. *Tetrahedron Lett.* **2002**, *43*, 3841–3844. Coelho, F.; Rossi, R. C. *Tetrahedron Lett.* **2002**, *43*, 2797–2800. Tominaga, K.; Sasaki, Y. *Synlett.* **2002**, 307–309. Lei, A. W.; Liu, G. S.; Lu, X. Y. *J. Org. Chem.* **2002**, *67*, 974–980. Overman, L. E.; Remarchuk, T. P. *J. Am. Chem. Soc.* **2002**, *124*, 12–13. Enders, D.; Kalfass, U.; Nolte, B. *Synlett.* **2002**, 33–36. Liu, G. S.; Lu, X. Y. *Org. Lett.* **2001**, *3*, 3879–3882. Bertau, M.; Burli, M.; Hungerbuhler, E.; Wagner, P. *Tetrahedron: Asymm.* **2001**, *12*, 2103–2107. Cacchi, S.; Fabrizi, G.; Goggiani, A.; Zappia, G. *Org. Lett.* **2001**, *3*, 2539–2541. Ariza, X.; Pineta, O.; Urpi, F.; Vilarrasa, J. *Tetrahedron Lett.* **2001**, *42*, 4995–4999. Yu, C. Z.; Jiang, Y. Y.; Liu, B.; Hu, L. Q. *Tetrahedron Lett.* **2001**, *42*, 1449–1452.

(10) Dialkyl carbonates were initially industrially prepared by the reaction between ROH and phosgene, the latter being in its turn obtained from the reaction between carbon monoxide and chlorine. In the past decades, methods based on oxidative carbonylation of alcohols have been developed (for recent reviews on the production and chemistry of dialkyl carbonates, see: Tundo, P.; Selva, M. *Acc. Chem. Res.* **2002**, *35*, 706–716; Delledonne, D.; Rivetti, F.; Romano, U. *Appl. Catal. A: Gen.* **2001**, *221*, 241–251). Clearly, the possibility to synthesize **2** starting directly from carbon monoxide rather than dialkyl carbonates represents an advantage from the standpoint of atom economy.⁸

(11) Chiral oxazolidin-2-ones are widely used as chiral auxiliaries in many important asymmetric syntheses. For reviews, see: Evans, D. A. *Aldrichim. Acta* **1982**, *15*, 23–32. Ager, D. J.; Prakash, I.; Schaad, D. R. *Chem. Rev.* **1996**, *96*, 835–875. Ager, D. J.; Prakash, I.; Schaad, D. R. *Aldrichim. Acta* **1997**, *30*, 3–12. For some recent examples, see: Wu, Y. K.; Shen, X.; Tang, C. J.; Chen, Z. L.; Hu, Q.; Shi, W. *J. Org. Chem.* **2002**, *67*, 3802–3810. Wu, Y. K.; Shen, X.; Tang, C. J.; Chen, Z. L. *Helv. Chim. Acta* **2001**, *84*, 3428–3432. Fanta, G.; Paio, A.; Quadrelli, P.; Rancati, F.; Senesi, P. *Tetrahedron* **2001**, *57*, 8313–8322.

(12) Some molecules containing the oxazolidin-2-one moiety have shown interesting pharmaceutical activity. For recent leading references, see: Ahmed, S.; Adat, S.; Murrells, A.; Owen, C. P. *Biochem. Biophys. Res. Commun.* **2002**, *294*, 380–383. Mai, A.; Artico, M.; Esposito, M.; Sbardella, G.; Massa, S.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B. *J. Med. Chem.* **2002**, *45*, 1180–1183; Seki, M.; Mori, K. *Eur. J. Org. Chem.* **1999**, 2965–2967.

respectively. IR spectra were taken on a FT-IR spectrometer. Electronic impact (EI) mass spectra were obtained at 70 eV on a GC-MS apparatus. Electrospray (ES) MS spectra were taken on 1/1 MeOH/H₂O solutions in the presence of 1% AcOH using an ES-MS apparatus. All reactions were analyzed by TLC on silica gel 60 F₂₅₄ or by GLC using capillary columns with polymethylsilicone + 5% phenylsilicone as the stationary phase. *R_f* in TLC were as follows: **2a**, 0.64 (1:9 hexane/acetone); **2b**, 0.30 (1:1 hexane/acetone); **2c**, 0.36 (1:1 hexane/acetone); **2d**, 0.28 (4:6 hexane/acetone); **2e**, 0.19 (1:1 hexane/AcOEt); **2f**, 0.22 (Et₂O); **2g**, 0.19 (Et₂O); **5**, 0.45 (7:3 hexane/AcOEt); **6**, 0.35 (7:3 hexane/AcOEt). Column chromatography was performed on silica gel 60 (70–230 mesh). Starting materials **1a–g** and **4** were commercially available and were used without further purification.

Carbonylation Procedure. Oxidative carbonylation reactions were carried out in a 300 mL stainless steel autoclave with magnetic stirring. In a typical experiment, the autoclave was charged in the presence of air with PdI₂, KI, and a solution of the substrate (5–15 mmol) in DME. The autoclave was pressurized at room temperature with stirring with CO (16 atm) and air (up to 20 atm of total pressure) and then heated at 100 °C with stirring for the required time. Reaction times, substrate/KI/PdI₂ molar ratios, and substrate concentration are indicated in Tables 1 and 2. After cooling, the autoclave was slowly degassed. In some cases (Table 1, entries 3, 6–8) oxamide derivatives **3** were present in suspension as colorless solids; they were easily separated by filtration and purified by washing with cold acetone. After removal of DME by rotary evaporation, crude products **2**, **5**, and **6** were purified as described below.

Separation and Characterization of Products. Crude products **2** were easily purified by column chromatography on silica gel using as eluent hexane/acetone from 1:1 to 4:6 (**2a**, **2c**); 6:4 hexane/acetone (**2b**); 1:1 hexane/acetone (**2d**); hexane/AcOEt from 9:1 to 7:3 (**2e**); hexane/Et₂O from 3:7 to 0:10 (**2f**); hexane/Et₂O from 3:7 to 0:10 (**2g**), and were fully characterized by IR, ¹H NMR and ¹³C spectroscopies, and MS spectrometry. Oxazolidin-2-ones were obtained with a satisfactory degree of purity, as confirmed by elemental analysis, so in the case of solid compounds (**2a**, **2c**, **2e**, **2f**, **2g**) no further purification by crystallization was needed. Products **5**, **6** were separated in this order by column chromatography on silica gel using hexane/AcOEt from 7:3 to 1:1; benzoxazolidin-2-one **5** thus obtained was a pale yellow solid that could be further purified by repeated crystallization from cold Et₂O to give a colorless solid. Compounds **3** were purified as described above. Also products **3**, **5**, and **6** were fully characterized by spectroscopic techniques and elemental analysis.

Oxazolidin-2-one 2a (colorless solid, mp 87–88 °C, lit.¹⁴ 88–89 °C): IR (KBr) 3274, 1731 cm⁻¹; ¹H NMR (acetone-*d*₆) δ 6.63 (br s, 1 H), 4.42–4.35 (m, 2 H), 3.63–3.56 (m, 2 H); ¹³C NMR (acetone-*d*₆) δ 160.8, 65.4, 41.1; MS (EI) *m/e* 87 (100, M⁺), 59 (44), 42 (24). Anal. Calcd for C₃H₅NO₂: C, 41.38; H, 5.79; N, 16.09. Found C, 41.48; H, 5.80; N, 16.05.

5-Methyloxazolidin-2-one 2b (pale yellow oil): IR (neat) 3299, 1739 cm⁻¹; ¹H NMR (acetone-*d*₆) δ 6.61 (br s, 1 H), 4.79–4.66 (m, 1 H), 3.73–3.66 (m, 1 H), 3.20–3.13 (m, 1 H), 1.37 (d, *J* = 6.4, 3 H); ¹³C NMR (acetone-*d*₆) δ 160.2, 73.6, 47.8, 20.7; MS (EI) *m/e* 101 (100, M⁺), 86 (17), 56 (57). Anal. Calcd for C₄H₇NO₂: C, 47.52; H, 6.98; N, 13.85. Found C, 47.47; H, 6.99; N, 13.89.

5-Phenyloxazolidin-2-one 2c (colorless solid, mp 90–91 °C, lit.¹⁴ 90–92 °C): IR (KBr) 3278, 1721 cm⁻¹; ¹H NMR (acetone-

*d*₆) δ 7.46–7.30 (m, 5 H), 6.75 (br s, 1 H), 5.63 (dd, *J* = 8.8, 7.3, 1 H), 4.00 (td, *J* = 8.8, 1.0, 1 H), 3.46 (ddd, *J* = 8.8, 7.3, 1.0, 1 H); ¹³C NMR (acetone-*d*₆) 159.8, 140.6, 129.5, 129.3, 126.6, 77.9, 48.7; MS (EI) *m/e* 163 (20, M⁺), 107 (100), 79 (37). Anal. Calcd for C₉H₉NO₂: C, 66.25; H, 5.56; N, 8.58. Found C, 66.31; H, 5.55; N, 8.60.

4-Methyloxazolidin-2-one 2d (pale yellow oil): IR (neat) 3287, 1743 cm⁻¹; ¹H NMR (acetone-*d*₆) δ 6.82 (br s, 1 H), 4.46 (t, *J* = 8.3, 1 H), 4.06–3.94 (m, 1 H), 3.89 (dd, *J* = 8.3, 6.3, 1 H), 1.24 (d, *J* = 5.9, 3 H); ¹³C NMR (acetone-*d*₆) δ 160.0, 71.9, 48.8, 20.8; MS (EI) *m/e* 101 (25, M⁺), 86 (100). Anal. Calcd for C₄H₇NO₂: C, 47.52; H, 6.98; N, 13.85. Found C, 47.58; H, 7.00; N, 13.88.

(R)-4-Phenyloxazolidin-2-one 2e (colorless solid, mp 130–131 °C, lit.¹⁴ 131–132 °C): IR (KBr) 3249, 1741, 1706 cm⁻¹; ¹H NMR (acetone-*d*₆) δ 7.42–7.30 (m, 5 H), 7.16 (br s, 1 H), 5.03 (ddd, *J* = 8.5, 6.6, 1.0, 1 H), 4.73 (t, *J* = 8.5, 1 H), 4.06 (dd, *J* = 8.5, 6.6, 1 H); ¹³C NMR (acetone-*d*₆) δ 159.9, 142.0, 129.7, 128.9, 126.9, 72.7, 56.6; MS (EI) *m/e* 163 (46, M⁺), 133 (75), 105 (74), 104 (100). Anal. Calcd for C₉H₉NO₂: C, 66.25; H, 5.56; N, 8.58. Found C, 66.41; H, 5.56; N, 8.57.

4-Isopropylloxazolidin-2-one 2f (colorless solid, mp 70–71 °C, lit.¹⁵ 69–72 °C): IR (KBr) 3243, 1747 cm⁻¹; ¹H NMR (CDCl₃) δ 7.45 (br s, 1 H), 4.45 (t, *J* = 8.8, 1 H), 4.10 (dd, *J* = 8.8, 6.4, 1 H), 3.68–3.59 (m, 1 H), 1.73 (octuplet, *J* = 6.8, 1 H), 0.97 (d, *J* = 6.8, 3 H), 0.90 (d, *J* = 6.8, 3 H); ¹³C NMR (CDCl₃) δ 160.9, 68.7, 58.5, 32.7, 18.0, 17.7; MS (EI) *m/e* 129 (4, M⁺), 86 (100), 85 (39). Anal. Calcd for C₆H₁₁NO₂: C, 55.80; H, 8.58; N, 10.84. Found C, 55.71; H, 8.60; N, 10.81.

(S)-4-Benzyloxazolidin-2-one 2g (colorless solid, mp 87–88 °C, lit.¹⁶ 87–88 °C): IR (KBr) 3286, 1755, 1710 cm⁻¹; ¹H NMR (acetone-*d*₆) δ 7.35–7.20 (m, 5 H), 6.84 (br s, 1 H), 4.34 (dd, *J* = 8.3, 7.8, 1 H), 4.20–4.11 (m, 1 H), 4.07 (distorted dd, *J* = 8.3, 5.4, 1 H), 2.96–2.81 (m, 2 H); ¹³C NMR (acetone-*d*₆) δ 159.7, 137.8, 130.2, 129.4, 127.5, 69.6, 54.2, 41.7; MS (EI) *m/e* 177 (3, M⁺), 92 (100), 91 (65), 86 (79). Anal. Calcd for C₁₀H₁₁NO₂: C, 67.78; H, 6.26; N, 7.90. Found C, 67.93; H, 6.27; N, 7.92.

***N,N*-Bis(2-hydroxy-2-phenylethyl)oxalamide 3c** (colorless solid, mp 166–167 °C): IR (KBr) 3426, 3305, 1654 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 8.50 (t, *J* = 5.5, 2 H), 7.36–7.23 (m, 10 H), 5.58 (d, *J* = 4.4, 2 H), 4.77–4.67 (m, 2 H), 3.41–3.25 (m, 4 H); ¹³C NMR (DMSO-*d*₆) δ 159.6, 143.1, 128.0, 127.1, 125.9, 70.5, 46.8; MS (ES) 367 (M + K)⁺, 351 (M + Na)⁺, 329 (M + H)⁺. Anal. Calcd for C₁₈H₂₀N₂O₄: C, 65.84; H, 6.14; N, 8.53. Found C, 65.91; H, 6.12; N, 8.51.

***N,N*-Bis(1-hydroxymethyl-2-methylpropyl)oxalamide 3f** (colorless solid, mp 186–187 °C): IR (KBr) 3419, 3298, 1640 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 8.19 (d, *J* = 9.3, 2 H), 4.74–4.67 (m, 2 H), 3.61–3.42 (m, 6 H), 1.85 (octuplet, *J* = 6.8, 2 H), 0.88 (d, *J* = 6.8, 6 H), 0.81 (d, *J* = 6.8, 6 H); ¹³C NMR (DMSO-*d*₆) δ 159.8, 60.9, 56.7, 28.5, 19.5, 18.6; MS (EI) *m/e* 260 (2, M⁺), 229 (47), 72 (100). Anal. Calcd for C₁₂H₂₄N₂O₄: C, 55.36; H, 9.29; N, 10.76. Found C, 55.42; H, 9.27; N, 10.78.

(S,S)-*N,N*-Bis(1-benzyl-2-hydroxyethyl)oxalamide 3g (colorless solid, mp 217–218 °C, lit.¹⁷ 217–217.5 °C): IR (KBr) 3420, 3301, 1656 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 8.35 (d, *J* = 9.3, 2 H), 7.27–7.12 (m, 10 H), 4.89 (t, *J* = 5.6, 2 H), 4.02–3.87 (m, 2 H), 3.44–3.32 (m, 4 H), 2.85 (distorted dd, *J* = 13.7, 5.4, 2 H), 2.71 (distorted dd, *J* = 13.7, 8.8, 2 H); ¹³C NMR (DMSO-*d*₆) δ 159.4, 138.7, 128.9, 128.0, 125.9, 62.1, 52.9, 36.0; MS (ES) 395 (M + K)⁺, 379 (M + Na)⁺. Anal. Calcd for C₂₀H₂₄N₂O₄: C, 67.40; H, 6.79; N, 7.86. Found C, 67.31; H, 6.80; N, 7.86.

3*H*-Benzooxazol-2-one 5 (colorless solid, mp 138–139 °C, lit.¹⁸ 137–139 °C): IR (KBr) 3230, 1776, 1737 cm⁻¹; ¹H NMR (CD₃OD) δ 7.20–7.04 (m, 4 H), 5.09 (br s, 1 H); ¹³C NMR (CD₃-OD) δ 157.2, 145.3, 131.5, 125.1, 123.4, 110.9, 110.6; MS (EI)

(13) Recently, oxazolidin-2-ones have also found application as synthetic intermediates. For some leading references, see: Knight, J. G.; Tchabanenko, K. *Tetrahedron* **2002**, *58*, 6659–6664. Shen, Y. H.; Friestad, G. K. *J. Org. Chem.* **2002**, *67*, 6236–6239. Marcantoni, E.; Mecozzi, T.; Petrini, M. *J. Org. Chem.* **2002**, *67*, 2989–2994. Gaul, C.; Seebach, D.; *Helv. Chim. Acta* **2002**, *85*, 772–787. Feroci, M.; Inesi, A.; Palombi, L.; Rossi, L. *Tetrahedron: Asymmetry* **2001**, *12*, 2331. Morita, T.; Nagasawa, Y.; Yashiro, S.; Matsunaga, H.; Kunieda, T. *Org. Lett.* **2001**, *3*, 897–899. Ishibashi, H.; Uegaki, M.; Sakai, M.; Takeda, Y. *Tetrahedron* **2001**, *57*, 2115–2120.

(14) Kubota, Y.; Kodaka, M.; Tomohiro, T.; Okuno, H. *J. Chem. Soc., Perkin Trans. 1* **1993**, 5–6.

(15) Palaty, Y.; Abbott, F. S. *J. Med. Chem.* **1995**, *38*, 3398–3406. (16) Moreno-Mañas, M.; Padros, I. *J. Heterocycl. Chem.* **1993**, *30*, 1235–1239.

(17) Denmark, S. E.; Stavenger, R. A.; Faucher, A.-M.; Edwards, J. P. *J. Org. Chem.* **1997**, *62*, 3375–3389.

(18) King, S. W.; Natarajan, R.; Bembli, R.; Fife, T. H. *J. Am. Chem. Soc.* **1992**, *114*, 10715–10721.

m/e 135 (100, M⁺), 91 (15), 79 (37). Anal. Calcd for C₇H₅NO₂: C, 62.22; H, 3.73; N, 10.37. Found C, 62.09; H, 3.73; N, 10.40.

2-Aminophenoxazin-3-one 6 [brown red solid, mp 256–257 °C (dec), lit. 254–256 °C,^{6a} 256–258^{6b}]: IR (KBr) 3413, 3307, 1587 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 7.74–7.70 (m, 1 H), 7.54–7.37 (m 3 H), 6.85 (br s, 2 H), 6.37 (s, 1 H), 6.36 (s, 1 H); ¹³C NMR (DMSO-*d*₆) δ 180.1, 148.8, 148.1, 147.3, 141.8, 133.6, 128.7, 127.9, 125.2, 115.8, 103.3, 98.2; MS (EI) *m/e* 212 (100, M⁺), 185

(60). Anal. Calcd for C₁₂H₈N₂O₂: C, 67.92; H, 3.80, N, 13.20. Found C, 68.09; H, 3.81; N, 13.17.

Acknowledgment. Financial support from the Ministero dell'Istruzione, dell'Università e della Ricerca is gratefully acknowledged (Progetto d'Interesse Nazionale PIN MM03027791).

JO026532A